PMID- 23396212
OWN - NLM
STAT- MEDLINE
DCOM- 20140314
LR  - 20130416
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 19
IP  - 5
DP  - 2013 May
TI  - Nonmalignant late effects in survivors of partially matched donor hematopoietic 
      stem cell transplantation.
PG  - 777-83
LID - S1083-8791(13)00062-1 [pii]
LID - 10.1016/j.bbmt.2013.01.026 [doi]
AB  - Human leukocyte antigen (HLA) partially matched related donor (PMRD) 
      hematopoietic stem cell transplantation (HSCT) is an effective option for 
      hematological malignancies. In this study, the nonmalignant late effects of PMRD 
      HSCT were evaluated and compared with HLA-identical sibling donor (ISD) HSCT. 
      Three hundred thirteen patients (ISD, n = 160; PMRD, n = 153) who survived at 
      least 6 months and received regular follow-up examinations after their HSCT were 
      enrolled. The 5-year cumulative incidence (+/-SE) of at least one late effect and 
      multiple late effects was 47.30% +/- .17% versus 58.21% +/- .16% (P = .134) and 
      17.97% +/- .10% versus 34.28% +/- .15% (P = .001) for PMRD HSCT recipients versus ISD 
      HSCT recipients, respectively. The cumulative incidence of keratoconjunctivitis 
      sicca, periodontitis, ankylosis, myalgia, and nephrotic syndrome was lower among 
      PMRD HSCT recipients compared with ISD HSCT recipients. Severe chronic 
      graft-versus-host disease, multiple pre-HSCT chemotherapy cycles, female donor, 
      and older age were risk factors for at least one late effect. Female donor, older 
      age, and long-term immunosuppressive therapy were associated with multiple late 
      effects. In summary, PMRD HSCT recipients have a lower risk of late effects 
      compared with ISD HSCT recipients, possibly due to differences in protocols for 
      graft-versus-host disease prophylaxis, and long-term follow-up after 
      transplantation is recommended.
CI  - Copyright (c) 2013 American Society for Blood and Marrow Transplantation. Published 
      by Elsevier Inc. All rights reserved.
FAU - Mo, Xiao-Dong
AU  - Mo XD
AD  - Peking University People's Hospital & Institute of Hematology, Beijing Key 
      Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Peoples Republic 
      of China.
FAU - Xu, Lan-Ping
AU  - Xu LP
FAU - Liu, Dai-Hong
AU  - Liu DH
FAU - Zhang, Xiao-Hui
AU  - Zhang XH
FAU - Chen, Huan
AU  - Chen H
FAU - Chen, Yu-Hong
AU  - Chen YH
FAU - Han, Wei
AU  - Han W
FAU - Wang, Yu
AU  - Wang Y
FAU - Wang, Feng-Rong
AU  - Wang FR
FAU - Wang, Jing-Zhi
AU  - Wang JZ
FAU - Liu, Kai-Yan
AU  - Liu KY
FAU - Huang, Xiao-Jun
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130205
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Donor Selection
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Tissue Donors
MH  - Transplantation, Homologous
MH  - Young Adult
EDAT- 2013/02/12 06:00
MHDA- 2014/03/15 06:00
CRDT- 2013/02/12 06:00
PHST- 2012/10/17 00:00 [received]
PHST- 2013/01/30 00:00 [accepted]
PHST- 2013/02/12 06:00 [entrez]
PHST- 2013/02/12 06:00 [pubmed]
PHST- 2014/03/15 06:00 [medline]
AID - S1083-8791(13)00062-1 [pii]
AID - 10.1016/j.bbmt.2013.01.026 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2013 May;19(5):777-83. doi: 
      10.1016/j.bbmt.2013.01.026. Epub 2013 Feb 5.